Front Cover: Aniquinazoline B, a Fungal Natural Product, Activates the μ-Opioid Receptor (ChemMedChem 19/2024)

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2024-10-03 DOI:10.1002/cmdc.202481901

Roxana Damiescu, Dr. rer. nat. Mohamed Elbadawi, Dr. rer. nat. Mona Dawood, PD Dr. Sabine M. Klauck, Prof. Dr. Gerhard Bringmann, Prof. Dr. Thomas Efferth

{"title":"Front Cover: Aniquinazoline B, a Fungal Natural Product, Activates the μ-Opioid Receptor (ChemMedChem 19/2024)","authors":"Roxana Damiescu, Dr. rer. nat. Mohamed Elbadawi, Dr. rer. nat. Mona Dawood, PD Dr. Sabine M. Klauck, Prof. Dr. Gerhard Bringmann, Prof. Dr. Thomas Efferth","doi":"10.1002/cmdc.202481901","DOIUrl":null,"url":null,"abstract":"<p>The Front Cover shows the identification of the new natural product aniquinazoline B from the marine fungus <i>Aspergillus nidulans</i> by virtual drug screening of a chemical library with 40000 compounds. Aniquinazoline B binds to the μ-opioid receptor. The amino acid sequence of the human μ opioid receptor in the background represents the basis for the 3D structure enabling virtual drug screening. Biochemical and cell culture experiments confirmed the μ-opioid receptor agonizing effect. This compound may be a promising candidate in pain-management to fight the opioid crisis. More details can be found in article 10.1002/cmdc.202400213 by Thomas Efferth and co-workers. The figure was created with biorender.com and parts of the figure were retrieved from smart servier medical art (smart.servier.com).\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure>\n </p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202481901","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202481901","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

The Front Cover shows the identification of the new natural product aniquinazoline B from the marine fungus Aspergillus nidulans by virtual drug screening of a chemical library with 40000 compounds. Aniquinazoline B binds to the μ-opioid receptor. The amino acid sequence of the human μ opioid receptor in the background represents the basis for the 3D structure enabling virtual drug screening. Biochemical and cell culture experiments confirmed the μ-opioid receptor agonizing effect. This compound may be a promising candidate in pain-management to fight the opioid crisis. More details can be found in article 10.1002/cmdc.202400213 by Thomas Efferth and co-workers. The figure was created with biorender.com and parts of the figure were retrieved from smart servier medical art (smart.servier.com).

查看原文本刊更多论文

封面：真菌天然产物 Aniquinazoline B 激活μ-类阿片受体（ChemMedChem 19/2024）

封面显示了通过对一个包含 40000 种化合物的化学文库进行虚拟药物筛选，从海洋真菌黑曲霉中鉴定出了新的天然产物 Aniquinazoline B。Aniquinazoline B 能与μ-阿片受体结合。背景中的人μ阿片受体氨基酸序列是虚拟药物筛选三维结构的基础。生化和细胞培养实验证实了μ-阿片受体的激动作用。这种化合物可能是治疗疼痛、应对阿片类药物危机的一种有前途的候选药物。更多详情可参见 Thomas Efferth 及其合作者撰写的文章 10.1002/cmdc.202400213。该图由 biorender.com 创建，部分内容取自 smart servier medical art (smart.servier.com)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.